Schering Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Jenapharm Gmbh & Co. Kg

Other

Helmholtz-zentrum Berlin Fuer Materialien Und Energie Gmbh

Jenapharm Gmbh

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Sven Ring

Walter Elger

Gerd Schubert

Ulrich Klar

Rolf Bohlmann

Katja Zimmermann

Thomas Frenzel

Joachim Kuhnke

Frederik Menges

Birgitt Schneider

Olaf Panknin

Guenter Kaufmann

Katja Prelle

Roland Neuhaus

Hans-Peter Muhn

Holger Siebeneicher

Hartmut Rehwinkel

Wolfgang Schwede

Duy Nguyen

Marcus Bauser

Sonja Anlauf

Sigfrid Schwarz

Stefan Kaulfuss

Ulf Bömer

Dirk Kosemund

Alexander Hillisch

Lars Bärfacker

Ludwig Zorn

Steffen Borden

Jan Hübner

Lothar Sobek

Bernd Erhart

Judith Günther

Ralf Wyrwa

Gerd Mueller

Paul Matthew Blaney

Ingo Tornus

G&uuml;nter Kaufmann

Martina Schäfer

Karl-Heinrich Fritzemeier

Andrea Rotgeri

Ulrich Bothe

Christa Hegele-Hartung

Martin Lange

Olaf Peters

Peter Droescher

Gudrun Reddersen

Holger Steuber

Horst Irlbacher

Nicole Schmidt

Bernd Undeutsch

Jan Huebner

Hans Peter Muhn

Harald Raethe

Peter Moellmann

Stefan Gall

Gerhard Teichmueller

Hans-Joachim Palme

Carmen Pfeiffer

Rutger Schlatmann

Gisela Weber

Guenther Kaufmann

Birgit Schneider

Hiroshi Yamanouchi

Frank Fink

Christof Schultz

Holger Rhein

Moshe Weizman

Andreas Von Deimling

Martina Schafer

Judith Gunther

Stefan Pusch

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Benzimidazol-2-amines as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I) in which R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

N-Methylbenzimidazoles as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

The present invention relates to benzimidazol-2-amines of general formula (I): in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Benzimidazol-2-amines as MIDH1 inhibitors

The present application relates to novel 6-substituted indazoles having a carboxamide side chain, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of endometriosis, lymphomas, macular degeneration, COPD and psoriasis.

Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments

A method for producing a rear-side contact system for a silicon thin-film solar cell having a pn junction formed from a silicon absorber layer and an emitter layer includes applying an organic insulation layer to the emitter layer; producing contact holes in the insulation layer as far as the absorber layer and the emitter layer; subsequently insulating the contact holes; subsequently applying a low-melting metal layer to form n and p contacts in the contact holes; separating the metal layer into n-contacting and p-contacting regions by laser-cutting; before applying the organic insulation layer to the emitter layer, applying a TCO layer; producing holes for contacts for the silicon absorber layer in the organic insulation; and subsequently selectively doping the produced holes for the contacts as far as the silicon absorber layer.

Method for producing a rear-side contact system for a silicon thin-layer solar cell

The invention relates to 17-(1'-propenyl)-17-3&#x2032;-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the residues Z, R, R, R, R, R, R, Rand Rhave the meanings stated in Claim, and their solvates, hydrates and salts, including all stereoisomers of these compounds. The invention further relates to the use of these derivatives for the production of a medicinal product for oral contraception and for the treatment of pre-, peri- and postmenopausal complaints and medicinal products that contain said derivatives, and in particular application in the aforementioned indications. The derivatives according to the invention have a progestational and in preferred cases additionally an antimineralocorticoid and neutral to slightly androgenic action. 

17-(1'propenyl)-17-3&#x2032;-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative

The 15&#x3b1;,16&#x3b1;-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid &#x3b3;-lactone derivatives of the present invention possess progestational efficacy. They have the general chemical formula I, in which Z is selected from the group comprising an oxygen atom, two hydrogen atoms, NOR and NNHSOR, where R is hydrogen, C-C-alkyl, aryl or C-C-aralkyl, Ris hydrogen or halogen, and moreover either: R, Rtogether form methylene or 1,2-ethanediyl or Ris hydrogen and Ris selected from the group comprising hydrogen, C-C-alkyl, C-C-alkenyl or C-C-alkynyl, and Ris selected from the group comprising hydrogen, C-C-alkyl, C-C-cycloalkyl, C-C-alkenyl or C-C-alkynyl, or: Ris hydrogen and Rand R, together, denote a bond, an oxygen or form methylene, Rrepresents hydrogen or C-C-alkyl and in addition include their solvates, hydrates, stereoisomers and salts. 

19-nor-steroid derivatives with a 15&#x3b1;,16&#x3b1;-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives

The invention relates to 17-hydroxy-19-nor-21-carboxylic acid-steroid &#x3b3;-lactone derivatives with the chemical formula I, where R, R, R, R, R, R, R, Rand Z have the meanings stated in claim, and their solvates, hydrates, stereoisomers and salts. The invention further relates to the use of these derivatives for the production of a medicinal product for oral contraception and for the treatment of pre-, peri- and postmenopausal complaints and medicinal products that contain said derivatives. The derivatives according to the invention have a progestational and in preferred cases additionally an antimineralocorticoid and neutral to slightly androgenic action. 

17-hydroxy-19-nor-21-carboxylic acid-steroid &#x3b3;-lactone derivative, use thereof, and medicament containing the derivative

The invention relates to 15,16-methylene-17-(1'-propenyl)-17-3&#x2032;-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the Z, R, R, R, Rand Rhave the meanings stated in claim, and solvates, hydrates and salts thereof, including all crystal modifications and all stereoisomers of these compounds. The invention also relates to the use of these derivatives for the production of a drug for oral contraception and for the treatment of pre-, peri- and postmenopausal problems and drugs which contain such derivatives, in particular use in the aforesaid indications. The derivatives according to the invention have a progestational and in preferable cases also an antimineralcorticoid and neutral to slight androgenic activity. 

15, 16-methylene-17-(1'-propenyl)-17,3&#x2032;-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative

The 17&#x3b2;-cyano-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSOR, in which R is hydrogen or C-C-alkyl, Ris hydrogen or halogen, furthermore either: R, Rtogether form methylene or 1,2-ethanediyl or Ris hydrogen and Ris selected from the group comprising hydrogen, methyl and hydroxymethylene, and Ris selected from the group comprising hydrogen, C-C-alkyl, C-C-alkenyl and cyclopropyl, or: Ris hydrogen and Rand Rtogether form methylene or are omitted with formation of a double bond between Cand C, R, Rare hydrogen or are omitted with formation of a double bond between Cand C, R, Rare hydrogen or together form methylene, Ris selected from the group comprising hydrogen, C-C-alkyl and allyl, where at least one of the substituents R, R, R, R, R, Rand Ris unequal to hydrogen or Rand Rare omitted with formation of a double bond between Cand C, and moreover comprise their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts. 

17&#x3b2;-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative

The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid, process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action.

Estradiol prodrugs

The present patent application relates to 11&#x3b2;-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones of formula I: wherein Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable to an androgen deficiency induced by glucocorticoids, especially cortisol.

11&#x3b2;-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones

The invention relates to &#x394;-D-homosteroids of general formula (I) process for their production and pharmaceutical compositions that contain these compounds. The compounds of general formula I according to the invention have androgenic activity.

[object Object]

Growing community of inventors

Jena, Germany

Sven Ring